Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo ...

Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Septerna’s stock jumped 69% in premarket trading after the deal was announced. Novo Nordisk’s stock rose 1.2% in European trading.

Danish drug manufacturer Novo Nordisk is partnering with California-based biotech Septerna to develop the latest pills to ...

Right now, leading weight-loss drugs must be injected into the body. Pill versions could make the drugs more convenient for patients and easier to ship and store. HealthDay News — Danish ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)'s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE ...